MedTech with Responsibility – Solutions that Connect

Interview with Laura Garcia Baglietto, Executive Vice President Medical Devices & Environment International of the GBA Group and Dr. Timo Lebold, Managing Director of GBA MDS GmbH

GBA Medical Device Services GmbH Microbiological Quality Control
Microbiological quality control includes determining the number of germs: This method can demonstrate how many viable microorganisms are present on a medical device – a critical step for product safety

The GBA Group is one of the leading laboratory and consulting service providers in the European Life Sciences sector. In Gilching near Munich, GBA Medical Device Services GmbH offers regulatory consulting and comprehensive analytics for manufacturers of medical devices. In the interview, Laura Garcia Baglietto and Dr. Timo Lebold discuss purpose, change, and collaborative solutions in medical technology.

Wirtschaftsforum: Ms. Garcia Baglietto, the GBA Group has grown significantly - what is behind this dynamic?

Laura Garcia Baglietto: We see ourselves as a life sciences service provider with a clear mission: we want to be a true partner to our clients by contributing to the market readiness of safe and effective products faster through our expertise in laboratory analytics, consulting and development. This is not an end in itself – we thereby make a direct contribution to patient safety, supply security, and ultimately to the quality of life. The GBA has been growing steadily since 1989 – we are now active in 13 countries with around 4,000 employees. Growth alone is not the goal: it is crucial that we make an impact with this growth.

Laura Garcia Baglietto, Executive Vice President Medical Devices & Environment International at GBA Group
Laura Garcia Baglietto, Executive Vice President Medical Devices & Environment International at GBA Group

Wirtschaftsforum: How does this effect manifest itself concretely, for example with MDS?

Dr. Timo Lebold: GBA Medical Device Services in Gilching is a good example. Since the integration two years ago, we have undertaken profound modernizations here. We rebuilt the site, quadrupled the lab space, and heavily invested in digitalization, automation, and skilled workers. All this while operating, which can certainly be described as surgery with the heart open. The goal was to respond quickly and reliably to rising demand in the medical technology sector – with efficient processes, short throughput times, and high analysis quality.

Dr. Timo Lebold, Managing Director of GBA MDS GmbH
Dr. Timo Lebold, Managing Director of GBA MDS GmbH

Wirtschaftsforum: Ms. Garcia Baglietto, how do you integrate this dynamic into the overall corporate strategy?

Laura Garcia Baglietto: For me, it is crucial that we leverage the strengths of our decentralized structure. The GBA is a group of very diverse, often entrepreneurially driven units. We do not homogenize but instead foster synergies where they make sense. Our task is to think about integration strategically: We connect know-how, create spaces for development, and nurture the entrepreneurial spirit within the group. Our approach is not only operationally driven but also culturally: We respect what has made our partner companies successful – and build on it. This keeps us adaptable, resilient, and close to the needs of our customers.

GBA Medical Device Services GmbH Headquarters
Comprehensive expertise: GBA Medical Device Services GmbH in Gilching

Wirtschaftsforum: What does that concretely mean for your customers?

Laura Garcia Baglietto: Our clients benefit from a strong network that can support every phase in the life cycle of a medical product: from development and testing to market surveillance. Especially for small and medium-sized enterprises, we are often a crucial partner in overcoming regulatory barriers and making a product market-ready at all. This can mean assisting in the creation of a licensing dossier or developing specific testing strategies – always with the goal to enable safe, sustainable products. And often behind the scenes. We are not loud, but we are decisive.

Contact Information GBA Medical Device Services GmbH Cell Culture Processes
Cell culture processes are used to test the biocompatibility of medical devices

Wirtschaftsforum: You talk about creating meaning – where do you personally find the meaning in your work?

Dr. Timo Lebold: I consider it a privilege to work in an area where quality measurably determines patient safety. When we do our job well, products are not only faster to market, but also safer and more reliable. This is service with conviction. If one day I myself need a medical product, then I want it to have been reviewed by a reliable partner – just like we do for our clients.

Laura Garcia Baglietto: I feel the same way. I have been in the laboratory industry for nearly 20 years now, and what continually drives me is this quiet but effective contribution: We enable innovation, ensure quality, support trust. I believe we have a societal responsibility, especially in the Life Sciences sector. 

GBA Medical Device Services GmbH Chemical Analysis
A detailed chemical analysis is conducted to identify ingredients and contaminants
GBA Medical Device Services GmbH Analyzer
With precise analyzers, samples are prepared and examined to identify even the smallest chemical components

Wirtschaftsforum: How do you plan to develop further in the coming years?

Dr. Timo Lebold: We have now created the structural basis to remain efficient in the long term. Our goal is not a short-term effect, but sustainable customer benefit. This way, we will maintain our agility and efficiency, further develop our portfolio strategically, and not lose sight of our values. Economic success is a means to an end, not an end in itself.

Laura Garcia Baglietto: As a service provider, we want to not only react but actively shape developments. In a dynamic field like medical technology, this is essential. If we do this with passion, excellence, and foresight, then we not only shape markets, we create real added value for health and society.

More Articles on Topic

Relief for Blind and Visually Impaired People Through AI

Interview with Klaus Knüpfer, CEO of EV Optron GmbH

Relief for Blind and Visually Impaired People Through AI

EV Optron is recognized as a manufacturer of products for blind users as well as reading and reading aloud devices for people with visual impairments: a Te...

More than 'just' similar

Interview with Mag. Helmut Kaisergruber, Managing Director and Co-owner, and Dr. Sabine Möritz-Kaisergruber, Managing Director and Co-owner of Astro Pharma GmbH

More than 'just' similar

Biosimilars, high-quality subsequent products of biologics, are increasingly gaining importance in the international health market. As a cost-effective...

Meeting patients at their needs

Interview with Alexander Fröhlich, Vice President DACH and General Manager of Dexcom Deutschland GmbH and Dr. Michael Struck, Marketing Director DACH of Dexcom Deutschland GmbH

Meeting patients at their needs

Easing the daily life of people with diabetes is the goal of Dexcom Deutschland GmbH. The globally successful corporation Dexcom is one of the market leaders...

Forge of the Future in Technology

Interview with Andreas Fischer, Managing Director of erfi Ernst Fischer GmbH & Co. KG

Forge of the Future in Technology

A success story made in Freudenstadt – erfi shows how German small and medium-sized enterprises are shaping the technology world of tomorrow. The company erfi ...

Manfred Brinkmann, Managing Editor-in-Chief

Manfred Brinkmann

Managing Editor of European Business

Are You Shaping the Future of Business?

As Managing Editor-in-Chief, I am always searching for the next generation of leaders and innovators. If you are at the helm of a company making a significant impact, I invite you to connect with us. Let's share your vision with our audience of influentia.